jamanetwork.com
Recent research highlights how deteriorating kidney function in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) acts as a critical prognostic marker, influencing mortality rates significantly.
This article presents findings from a study assessing kidney function decline as a prognostic marker in transthyretin amyloid cardiomyopathy (ATTR-CM) patients, showing its correlation with increased mortality risk.
In a cohort study of 2001 patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a decline in kidney function was identified as a significant prognostic marker for mortality. The study revealed that a deterioration in the estimated glomerular filtration rate (eGFR) by more than 20% at one year led to a 1.7-fold increased risk of mortality, independent of other clinical markers such as serum cardiac biomarkers. This finding suggests that kidney function monitoring should be a pivotal component in managing ATTR-CM, providing a crucial independent marker for disease progression and potential therapeutic intervention strategies.
Monitoring kidney function is vital for managing ATTR-CM. Declining kidney function is a significant prognostic marker for mortality in ATTR-CM.
Understanding the interplay between kidney function and cardiomyopathy is crucial in managing patients with cardiac conditions, particularly transthyretin amyloid cardiomyopathy (ATTR-CM). Recent studies have highlighted that declining kidney function is not merely a symptom but a significant prognostic marker.
"Decline in kidney function was frequently observed in patients with ATTR-CM and was consistently associated with an increased risk of mortality," said Adam Ioannou, a leading researcher in the study.
Ioannou's research underscores the necessity of incorporating kidney function monitoring as a standard practice for patients with ATTR-CM. This approach could not only improve risk stratification but also potentially enhance patient outcomes by informing treatment adjustments.
Statistical evidence supports the prognostic significance of kidney function. Statistical data firmly establishes the relationship between eGFR decline and mortality.
In the cohort study involving 2001 patients, a significant number experienced a decline in kidney function, defined by a decrease in estimated glomerular filtration rate (eGFR) by more than 20% at one year. These results were consistent across various genotypes and disease stages.
The study emphasizes that the risk of mortality increased by 1.7 times among those who experienced eGFR decline. Such compelling statistics indicate a need for clinicians to give due attention to kidney health in their treatment plans for ATTR-CM patients.
This statistical correlation bolsters the argument that vigilant kidney function monitoring should be a fundamental component of managing patients with ATTR-CM, enabling better prognostic evaluations and potentially informing therapeutic strategies.
Clinical practice should integrate kidney function monitoring in ATTR-CM management. Kidney function monitoring should be integrated into standard clinical practice for ATTR-CM.
The clinical implications of this study's findings point towards a paradigm shift in how transthyretin amyloid cardiomyopathy is managed. Given the strong correlation between eGFR decline and mortality, regular kidney function monitoring should become a standard practice.
"eGFR decline represents an independent marker of ATTR-CM disease progression that could guide treatment optimization in clinical practice," noted the research team.
Such insights are vital for developing comprehensive care plans that address not only the cardiac aspects of ATTR-CM but also potential kidney-related complications. By modifying treatment strategies based on kidney function, healthcare providers could potentially improve survival rates and quality of life for their patients.
Ioannou A, Razvi Y, Porcari A, et al. Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy. JAMA Cardiol. 2025;10(1):118-126. doi:10.1001/jamacardio.2024.6720.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872-2891. doi:10.1016/j.jacc.2019.04.003.
Ioannou A, Patel RK, Razvi Y, et al. Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis. JACC Cardiovasc Imaging. 2023;16(4):464-477. doi:10.1016/j.jcmg.2022.07.008.
Porcari A, Razvi Y, Masi A, et al. Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy. Eur J Heart Fail. 2023;25(4):515-524. doi:10.1002/ejhf.2776.